- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 1.1 EX-1.1
- 2.4 EX-2.4
- 4.34 EX-4.34
- 4.35 EX-4.35
- 4.36 EX-4.36
- 4.37 EX-4.37
- 4.38 EX-4.38
- 4.39 EX-4.39
- 4.40 EX-4.40
- 4.41 EX-4.41
- 4.42 EX-4.42
- 4.43 EX-4.43
- 4.44 EX-4.44
- 4.45 EX-4.45
- 4.46 EX-4.46
- 4.47 EX-4.47
- 4.48 EX-4.48
- 8 EX-8
- 12.1 EX-12.1
- 12.2 EX-12.2
- 13.1 EX-13.1
- 13.2 EX-13.2
- 15.1 EX-15.1
- Download Excel data file
- View Excel data file
Exhibit 13.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
I, Jens Holstein, Chief Financial Officer of BioNTech SE (the “Company”), certify that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 27, 2023 | By: | /s/ Jens Holstein | ||||
Jens Holstein | ||||||
Chief Financial Officer |